Merck news from FierceBiotech
NewsMerck turns to Ranbaxy for $100M R&D effort
India's Ranbaxy has flexed its research muscles once again, this time signing a five-year pact with Merck to develop new anti-infectives. Ranbaxy, which received an undisclosed upfront payment, says Read more...
Traditional remedies offer opportunities, challenges
The Financial Times delves into the push to develop new therapeutics from traditional Chinese and Indian remedies. There have been successes, including the anti-malarial artemether, which was Read more...
Analyst predicts a long delay for Merck's Cordaptive
There's more bad news--or analysis--for Merck's drug development efforts. After the FDA Read more...
Merck wins the 'silver' for worst news week
WBB Securities analyst Steve Brozak has issued a symbolic "silver medal" to Merck for worst news week. In a triple whammy rarely accomplished in the drug world, Merck had two experimental Read more...
Merck shares hammered after FDA rejects Cordaptive
Shares of Merck were sliding again this morning on the news that the FDA has turned thumbs down on MK-0524A, its new cholesterol therapy. The stock dropped eight percent after regulators announced Read more...
Avastin, Erbitux battle for lung cancer market
Genentech's stock was down this morning on results from a Phase III study of Avastin for non-small cell lung cancer. While the drug did meet the primary endpoint--an improvement in progression-free Read more...
Dynavax shares hammered on FDA clinical hold
Dynavax's shares took a beating this morning after the FDA placed a clinical hold on the company's trial of Heplisav, a hepatitis B therapy. According to the Motley Fool, "[t]he agency put the Read more...
Codexis blueprints $100 million IPO
Codexis has decided to wade into frigid market waters with an IPO that may be used to raise upwards of $100 million. The company makes biocatalysts: enzymes or microbes that cause chemical Read more...
ALSO NOTED: Crucell shares up on TB data; Celera, Merck ink cancer deal; and much more...
> A federal patent office may appeal a court ruling that threw out a new cap limiting the number of times a company can resubmit patent applications. That change was aggressively contested by the Read more...
| Press ReleasesCelera Genomics Group-an Applera Corp. Business Grants License to Merck for Cancer Targets Celera Genomics Group-an Applera Corp. Business Grants License to Merck for Cancer Targets /10/2008 ALAMEDA, Calif. -- Celera, an Applera Corporation business, today announced a two year exclusive Read more... Experimental Weight-loss Drug Cuts Appetite, Burns More Energy, Study Suggests Experimental Weight-loss Drug Cuts Appetite, Burns More Energy, Study Suggests The first clinical studies of an experimental drug have revealed that obese people who take it for 12 weeks lose Read more... Merck Sells Pennsylvania Chemicals Plant Merck Sells Pennsylvania Chemicals Plant PHILADELPHIA, Jan. 1 -- PRWT Services, Inc., a minority-owned business enterprise, today announced that it has, through its wholly-owned subsidiary, Cherokee Read more... PRESS RELEASE: Idera Pharmaceuticals, and Merck Forge $400 Million Cancer Drug Deal Idera Pharmaceuticals, and Merck Forge $400 Million Cancer Drug Deal CAMBRIDGE, Mass. -- Idera Pharmaceuticals announced today that it has entered into a worldwide licensing and collaboration Read more... PRESS RELEASE: Merck Announces Voluntary Recall of Certain Lots of PEDVAXHIB and COMVAX Merck Announces Voluntary Recall of Certain Lots of PEDVAXHIB and COMVAX WHITEHOUSE STATION, N.J., Dec. 12, 2007 - Merck & Co., Inc. announced today that the Company has initiated a voluntary Read more... |
Get more Merck coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight